临床与转化科学奖（CTSA）药物资产门户——一种药物重新定位的公私合作模式。
The CTSA Pharmaceutical Assets Portal - a public-private partnership model for drug repositioning.
作者信息
Marusina Kate, Welsch Dean J, Rose Lynn, Brock Doug, Bahr Nathan
机构信息
Clinical and Translational Science Center, University of California, Davis, Sacramento, CA 95817, United States.
出版信息
Drug Discov Today Ther Strateg. 2011 Winter;8(3-4):77-83. doi: 10.1016/j.ddstr.2011.06.006.
Abstract
The Pharmaceutical Assets Portal aims to facilitate industry-academic collaborations for discovery of new indications for compounds no longer being developed by pharmaceutical companies, through eliminating barriers to access such compounds. The Portal's enabling infrastructure includes a national investigator database; a Foci-of-Expertise browser; a material transfer agreement template; and a funding partner. Whereas the goal of creating a shared compound repository remains to be achieved, the Portal has established a mechanism to facilitate future drug repositioning opportunities.
摘要
药品资产门户网站旨在通过消除获取此类化合物的障碍，促进产学研合作，以发现制药公司不再研发的化合物的新适应症。该门户网站的支持性基础设施包括一个全国性的研究人员数据库、一个专业领域浏览器、一份材料转让协议模板以及一个资助合作伙伴。虽然建立共享化合物储存库的目标仍有待实现，但该门户网站已建立了一种机制，以促进未来的药物重新定位机会。
相似文献
1
The CTSA Pharmaceutical Assets Portal - a public-private partnership model for drug repositioning.临床与转化科学奖（CTSA）药物资产门户——一种药物重新定位的公私合作模式。
Drug Discov Today Ther Strateg. 2011 Winter;8(3-4):77-83. doi: 10.1016/j.ddstr.2011.06.006.
2
Project-Based Public-Private Collaborations.基于项目的公私合作。
Handb Exp Pharmacol. 2024;286:21-31. doi: 10.1007/164_2024_722.
3
Developing research collaborations and building capacity in palliative and end-of-life care in the North West Coast of England: the PalCaRe-NWC partnership.在英格兰西北海岸开展姑息治疗和临终关怀方面的研究合作并建设相关能力：PalCaRe-NWC伙伴关系。
Public Health Res (Southampt). 2025 Mar 19:1-13. doi: 10.3310/AWLT2995.
4
Academic medical product development: an emerging alliance of technology transfer organizations and the CTSA.学术性医疗产品开发：技术转移组织与临床与转化科学奖联盟的新兴合作关系
Clin Transl Sci. 2014 Dec;7(6):456-64. doi: 10.1111/cts.12175. Epub 2014 Jun 19.
5
A public-private collaboration model for clinical innovation.公私合作模式用于临床创新。
Clin Transl Sci. 2022 Jul;15(7):1581-1591. doi: 10.1111/cts.13293. Epub 2022 May 22.
6
Drug repurposing: a systematic review on root causes, barriers and facilitators.药物再利用：根源、障碍和促进因素的系统评价。
BMC Health Serv Res. 2022 Jul 29;22(1):970. doi: 10.1186/s12913-022-08272-z.
7
A protocol for developing an evaluation framework for an academic and private-sector partnership to assess the impact of major food and beverage companies' investments in community health in the United States.一项关于制定评估框架的方案，该框架用于评估学术机构与私营部门合作关系，以评估美国主要食品和饮料公司在社区健康方面投资的影响。
BMC Obes. 2015 Sep 24;2:36. doi: 10.1186/s40608-015-0066-0. eCollection 2015.
8
Quantitative assessment of the impact of standard agreement templates on multisite clinical trial start up time.标准协议模板对多中心临床试验启动时间影响的定量评估。
J Clin Transl Sci. 2023 Sep 6;7(1):e204. doi: 10.1017/cts.2023.622. eCollection 2023.
9
"Asset exchange"-interactions between patient groups and pharmaceutical industry: Australian qualitative study.“资产交换”-患者群体与制药行业的互动：澳大利亚定性研究。
BMJ. 2019 Dec 12;367:l6694. doi: 10.1136/bmj.l6694.
10
Public-Private Partnerships: Compound and Data Sharing in Drug Discovery and Development.公私合作伙伴关系：药物发现和开发中的化合物和数据共享。
SLAS Discov. 2021 Jun;26(5):604-619. doi: 10.1177/2472555220982268. Epub 2021 Feb 13.
引用本文的文献
1
Drug Repurposing: A Conduit to Unravelling Metabolic Reprogramming for Cancer Treatment.药物再利用：揭示癌症治疗中代谢重编程的途径。
Mini Rev Med Chem. 2025;25(8):601-627. doi: 10.2174/0113895575339660250106093738.
2
Small Molecules as Toll-like Receptor 4 Modulators Drug and Computational Repurposing.作为Toll样受体4调节剂的小分子：药物与计算性重新利用
Biomedicines. 2022 Sep 19;10(9):2326. doi: 10.3390/biomedicines10092326.
3
Drug repurposing: a systematic review on root causes, barriers and facilitators.药物再利用：根源、障碍和促进因素的系统评价。
BMC Health Serv Res. 2022 Jul 29;22(1):970. doi: 10.1186/s12913-022-08272-z.
4
What, Where, When and How of COVID-19 Patents Landscape: A Bibliometrics Review.新冠疫情专利态势的相关要素：文献计量学综述
Front Med (Lausanne). 2022 Jul 1;9:925369. doi: 10.3389/fmed.2022.925369. eCollection 2022.
5
Exploring new uses for existing drugs: innovative mechanisms to fund independent clinical research.探索现有药物的新用途：为独立临床研究提供资金的创新机制。
Trials. 2021 May 4;22(1):322. doi: 10.1186/s13063-021-05273-x.
6
Repurposing FDA Approved Drugs as JNK3 Inhibitor for Prevention of Neuroinflammation Induced by MCAO in Rats.将美国食品药品监督管理局（FDA）批准的药物重新用作JNK3抑制剂，以预防大鼠大脑中动脉闭塞（MCAO）诱导的神经炎症。
J Inflamm Res. 2020 Dec 24;13:1185-1205. doi: 10.2147/JIR.S284471. eCollection 2020.
7
Drug Repurposing Is a New Opportunity for Developing Drugs against Neuropsychiatric Disorders.药物重新利用是开发抗神经精神疾病药物的新机遇。
Schizophr Res Treatment. 2016;2016:6378137. doi: 10.1155/2016/6378137. Epub 2016 Mar 17.
8
Computer-Aided Identification of Anticonvulsant Effect of Natural Nonnutritive Sweeteners Stevioside and Rebaudioside A.天然非营养性甜味剂甜菊糖苷和莱鲍迪苷A抗惊厥作用的计算机辅助鉴定
Assay Drug Dev Technol. 2015 Jul-Aug;13(6):313-8. doi: 10.1089/adt.2015.29010.meddrrr.
9
Warning letters to sponsor-investigators at academic health centres - the regulatory "canaries in a coal mine".致学术健康中心申办方研究者的警告信——监管领域的“煤矿中的金丝雀”
Clin Invest Med. 2013 Dec 1;36(6):E290-6. doi: 10.25011/cim.v36i6.20626.
10
Open-source approaches for the repurposing of existing or failed candidate drugs: learning from and applying the lessons across diseases.现有或失败的候选药物重新利用的开源方法：跨疾病借鉴并应用经验教训。
Drug Des Devel Ther. 2013 Aug 8;7:753-66. doi: 10.2147/DDDT.S46289. eCollection 2013.
本文引用的文献
1
The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics.NCGC 药物库：一个全面的临床批准药物资源，可用于药物重定位和化学生物基因组学。
Sci Transl Med. 2011 Apr 27;3(80):80ps16. doi: 10.1126/scitranslmed.3001862.
2
Reengineering the national clinical and translational research enterprise: the strategic plan of the National Clinical and Translational Science Awards Consortium.国家临床与转化研究企业的重塑：国家临床与转化科学奖联盟的战略计划。
Acad Med. 2010 Mar;85(3):463-9. doi: 10.1097/ACM.0b013e3181ccc877.
Zotero 插件